ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million

About this update from Abvc Biopharma, Inc.

[{"type":"image","caption":"","headline":"ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States","size":{"original":{"width":140,"height":78,"url":"https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X_qKvHxujBtXyrHhszohog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNztjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7","width":140,"height":78}}},{"type":"text","content":"FREMONT, CA - April 3, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced that its majority-owned subsidiary, AiBtl BioPharma Inc., has signed a strategic share-based land acquisition agreement with local landholders in central Taiwan. The transaction, valued at $7,666,667, involved the exchange of AiBtl shares priced at $5.00[1] per share and secured exclusive rights to agricultural land for future pharmaceutical production.","length":602,"tagName":"p"},{"type":"text","content":"The acquired land will be designated for the cultivation and extraction of Polygala tenuifolia (Yuan Zhi), a central ingredient in AiBtl's botanical drug candidates for Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD). The Company believes this move is key to reducing sourcing risk and supporting large-scale, high-quality production of active botanical compounds.","length":404,"tagName":"p"},{"type":"text","content":""This agreement is a long-term investment into securing the future of botanical drug innovation," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC. "By locking in upstream resources in Asia, we are strengthening AiBtl's infrastructure from seed to formulation - giving our neuroscience pipeline a sustainable foundation."","length":353,"tagName":"p"},{"type":"text","content":"The transaction also reflects ABVC's continuing efforts to expand its physical and operational footprint in the Asia-Pacific region while enhancing value for global shareholders.","length":182,"tagName":"p"},{"type":"text","content":"Strategic Context","length":17,"tagName":"p"},{"typ...

More updates from Abvc Biopharma, Inc.